calcium homeostasis modulator family member 5Genealiases: C6orf188 · FAM26E · dJ493F7.3
Q-omics provides the consensus-scored CALHM5 profile across patient tissues and cancer cell-line models. CALHM5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CALHM5 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CALHM5 RNA expression shows 21,789 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where CALHM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALHM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALHM5 survival associations across molecular data types. CALHM5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALHM5 RNA expression–survival associations across cancer types. High CALHM5 expression shows unfavorable associations in KIRP, MESO, BLCA, LGG and UVM, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CALHM5 RNA expression.
This table summarizes CALHM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CALHM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALHM5 shows lower tumor expression in KICH, KIRP, BLCA and UCEC and higher tumor expression in HNSC and STAD. The HNSC box plot shows higher CALHM5 RNA expression in tumor versus normal tissue (log2 FC = +1.273, t-test p < 0.001).
This table shows molecular features associated with CALHM5 in patient tissues and cancer cell lines. In patient samples, CALHM5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CALHM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
